Payment overview · 2025
General Payments
$272.31
13 reported records · 9 companies
Healthcare provider profile · identity verified
John K Miller, MD
Allopathic & Osteopathic Physicians|Family Medicine · WOOSTER, OH · NPI 1104910330
Verified facts
What the public records show
CMS Open Payments records show John K Miller, MD received $272.31 in general payments during 2025 across 13 reported records.
ABBVIE INC. accounted for 39.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $107.00 | 39.3% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.01 | 12.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.64 | 8.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.49 | 7.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.61 | 7.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.93 | 7.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.81 | 6.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.73 | 5.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.09 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $272.31 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $60.86 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.01 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.58 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 89 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
78 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
75 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 240 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 170 | 16 |
| Losartan Potassium | Losartan Potassium | 160 | 16 |
| Potassium Chloride | Potassium Chloride | 158 | 20 |
| Amlodipine Besylate | Amlodipine Besylate | 148 | 15 |
| Atorvastatin Calcium | Atorvastatin Calcium | 144 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 134 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 17 |
| Gabapentin | Gabapentin | 123 | 17 |
| Lisinopril | Lisinopril | 112 | suppressed |
| Eliquis | Apixaban | 89 | suppressed |
| Myrbetriq | Mirabegron | 78 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 77 | suppressed |
| Trulicity | Dulaglutide | 75 | suppressed |
| Mirtazapine | Mirtazapine | 67 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 62 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 59 | suppressed |
| Memantine Hcl | Memantine Hcl | 54 | suppressed |
| Famotidine | Famotidine | 52 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 51 | suppressed |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Metformin Hcl | Metformin Hcl | 49 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 48 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 45 | suppressed |
| Spironolactone | Spironolactone | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Clonazepam | Clonazepam | 43 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 41 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Prednisone | Prednisone | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Cephalexin | Cephalexin | 37 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Fentanyl | Fentanyl | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Mirabegron Er | Mirabegron | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | suppressed |
| Carvedilol | Carvedilol | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Enulose | Lactulose | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Omeprazole | Omeprazole | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $272.31 · 13 records | ABBVIE INC. | CREON, ELIQUIS, GVOKE HYPOPEN, JARDIANCE, Korlym, LINZESS, NURTEC ODT, QULIPTA, REXULTI, VOQUEZNA, VRAYLAR, Veozah, ZENPEP | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error